Core Viewpoint - Xianruida Medical-B (06669) has seen a significant stock price increase following the announcement of receiving registration approval for its micro-guide wire from the Beijing Drug Administration, which is intended for use in peripheral vascular applications [1] Group 1: Stock Performance - The stock price of Xianruida Medical-B rose over 12% in the afternoon session, with a current increase of 7.84%, trading at HKD 12.11, and a transaction volume of HKD 18.90 million [1] Group 2: Regulatory Approval - The company announced that it received registration approval for its micro-guide wire, which is designed for guiding and placing diagnostic or therapeutic devices in peripheral vascular applications [1] Group 3: Future Plans - Xianruida Medical plans to conduct marketing activities in China in a timely manner following the approval [1] - The company is set to hold a board meeting on August 26 to approve its interim results [1] Group 4: Acquisition and Collaboration - In December 2022, Boston Scientific initiated a takeover bid for Xianruida Medical, offering HKD 20 per share for up to 65% of the company's majority stake, with an estimated transaction value of approximately USD 523 million [1] - In July 2023, both parties signed a cooperation framework agreement and service framework agreement to collaborate in areas such as global commercialization, manufacturing services, and product development [1]
先瑞达医疗-B午后涨超12% 微导丝注册申请获批 公司和波士顿科学深度战略合作